After years of weight loss drug shortages, the FDA is saying there’s now an adequate supply for most medications and they ...

Compounding pharmacies will have to stop producing copycats of tirzepatide, the active ingredient in the blockbuster weight ...

From singing on Broadway to playing beloved characters on the big screen (including everyone's favorite animated snowman, ...

AbbVie Inc. enters the obesity market with GUBamy, a promising amylin analog. Click here to find out why ABBV stock is a Buy.

Vivani Medical (Nasdaq:VANI) announced today that it successfully administered the first GLP-1 implant in its LIBERATE-1 ...

NotCo announced Thursday the launch of its GLP Booster, a product that can be mixed into any food to naturally help you feel ...

Payers are raising alarm over their rising medical costs. What should revenue cycle leaders look out for as payers rein in their rising costs?

I’m trying to lose the 18 pounds I have gained since the pandemic. It has been hard enough that I’m wondering about Ozempic.

To be a person in the year 2025 is to encounter, in one way or another, the marketing onslaught for compounded ...

ELLE editors went on a deep dive to answer all of the most common questions about Ozempic and other similar drugs. Below, ...

Vivani Medical (VANI) announced the successful administration of its first GLP-1 or exenatide, implant in the LIBERATE-1 clinical trial. This ...

FDA ends GLP-1 drug shortage. Concerns over safety, counterfeit drugs, and high cost of brand-name versions persist; ...